Evidence map›Paper›PMID 33761014›Full record

ReviewCurrent pain and headache reports2021

Dual Enkephalinase Inhibitors and Their Role in Chronic Pain Management.

Warren A Southerland, Justin Gillis, Sumanth Kuppalli, Alex Fonseca, Andrew Mendelson, Storm V Horine, Nitin Bansal, Amitabh Gulati

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Warren A SoutherlandBeth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA. wsouther@bidmc.harvard.edu.ORCID http://orcid.org/0000-0003-4917-4485
Justin GillisBeth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Sumanth KuppalliBeth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Alex FonsecaBeth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA.
Andrew MendelsonDepartment of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Storm V HorineDepartment of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Nitin BansalDepartment of Anesthesiology, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Amitabh GulatiDepartment of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Beth Israel Deaconess Medical Center · USNewYork–Presbyterian Hospital · USMemorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDual enkephalinase inhibitors (DENKIs) are pain medications that indirectly activate opioid receptors and can be used as an alternative to traditional opioids. Understanding the physiology of enkephalins and their inhibitors and the pharmacology of these drugs will allow for proper clinical application for chronic pain patients in the future. RECENT

findingsDENKIs can be used as an alternative mode of analgesia for patients suffering from chronic pain by preventing the degradation of endogenous opioid ligands. By inhibiting the two major enkephalin-degrading enzymes (neprilysin and aminopeptidase N), DENKIs can provide analgesia with less adverse effects than nonendogenous opioids. The purpose of this paper is to review the current literature investigating DENKIs and explore their contribution to chronic pain management.

Indexed as

CD13 AntigensChronic PainDipeptidesDisulfidesEnkephalinsEnzyme InhibitorsHumansNeprilysinPhenylalaninePropionatesPropylamines1-(2-((1-ethoxycarbonyloxyethoxycarbonylmethyl)carbamoyl)-3-phenylpropyldisulfanylmethyl)-3-methylsulfanylpropylamineCD13 AntigensDipeptidesDisulfidesEnkephalinsEnzyme InhibitorskelatorphanNeprilysinPhenylalaninePL265PropionatesPropylaminesRB 101AnalgesiaChronic painEndogenous opioidEnkephalinase inhibitorsMultimodal analgesiaPain management

Identifiers

PMID33761014
OpenAlexW3136013191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.